Nagi Bioscience was awarded an Innosuisse Innovation Project in 2020.
Nagi Bioscience was named as a TOP 100 Swiss startups and TOP 10 newcomers of 2020. And we did it again this year 2022! We have been nominated for TOP 100 Swiss…
Nagi Bioscience was selected by the prestigious Swiss economic newspaper Bilan among the Top 50 startups in which to invest in 2020.
Nagi Bioscience raises CHF 1.8 Million to accelerate its mission of setting a new standard for testing safety and efficacy of drugs and chemicals.
Today, our CEO Matteo Cornaglia was on stage for pitching the company at the LaForge Startup Demo Day on EPFL campus. Good vibes and interesting connections with the attendees. Thank you La Forge…
We are glad to announce that our application was accepted by the Novartis Foundation for Medical-Biological Research. This research project will be coordinated in collaboration with the Laboratory of Microsystems at EPFL headed by the Prof….
Nagi Bioscience wins the final phase of Venture Kick (130’000 CHF). The Venture Kick program has been an excellent support in terms of network, visibility and advices received from the coach and jury. Thank…
Nagi Bioscience is among the 20 finalists of the competition “Inventer Demain” organized by the RTS, France 3TV and Bilan magazine. Ten Swiss start-ups and ten other French companies are competing this year. This…
We are proud to be the winner (CHF 10’000 cash prize) of the startup competition organized by Philip Morris Equity Partner! This competition, organized in the framework of MassChallenge Switzerland, aimed to support innovative…
Nagi Bioscience passed stage 2 of Venture Kick! Let’s continue on our way: stage 3, here we come!